Tenaya Therapeutics Inc (TNYA) Noticias

Form S-3 - Registration statement under Securities Act of 1933

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session

SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Tenaya Therapeutics Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a...

Form 3 - Initial statement of beneficial ownership of securities